<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003802</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J9875, CDR0000066946</org_study_id>
    <secondary_id>U01CA063437</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-98111005</secondary_id>
    <secondary_id>JHOC-JH9875</secondary_id>
    <secondary_id>JHOC-T96-0116</secondary_id>
    <secondary_id>NCI-T96-0116</secondary_id>
    <nct_id>NCT00003802</nct_id>
  </id_info>
  <brief_title>Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma</brief_title>
  <official_title>A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients&#xD;
      who have metastatic skin or eye melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the antitumor activity of pyrazoloacridine (PZA) in chemotherapy naive patients&#xD;
           with metastatic cutaneous or ocular melanoma.&#xD;
&#xD;
        -  Determine the toxic effects of PZA in this patient population.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of PZA in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified into cutaneous or ocular melanoma treatment groups.&#xD;
&#xD;
      Patients receive pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 21 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 28-70 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyrazoloacridine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic cutaneous or ocular melanoma that is chemotherapy&#xD;
             naive&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No pleural effusions or ascites&#xD;
&#xD;
          -  No untreated CNS metastases&#xD;
&#xD;
          -  Stable brain metastases by CT or MRI scan&#xD;
&#xD;
               -  At least 4 weeks since prior steroid therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN (unless due to hepatic metastases)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known hypersensitivity to E.coli derived proteins&#xD;
&#xD;
          -  No other serious medical problems&#xD;
&#xD;
          -  No more than 1 primary malignancy within past 5 years, other than:&#xD;
&#xD;
               -  Nonmelanomatous skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
          -  No history of spinal cord compression&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy allowed (e.g., interleukin-2, interferon alfa, or vaccine&#xD;
             therapy)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy for primary ocular melanoma, brain metastases, or to metastatic&#xD;
             sites encompassing less than 25% of the bone marrow allowed&#xD;
&#xD;
          -  No other prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H. Sharfman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2003</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>NSC 366140</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

